Drug intelligence / Profile preview

Pan-KRAS inhibitor (Leadingtac Pharmaceutical)

Development stage: Preclinical
Lead developer: Leadingtac
Modality: Small Molecules
Administration: Oral, Subcutaneous

Overview

Leadingtac Pharmaceutical's Pan-KRAS inhibitor is a small-molecule therapeutic designed to target multiple isoforms of the KRAS protein. Unlike allele-specific inhibitors that target single mutations such as G12C or G12D, this pan-KRAS approach is intended to inhibit a broader range of KRAS mutations, potentially addressing a wider patient population with KRAS-driven malignancies. The program is currently in the IND-enabling phase, with an Investigational New Drug (IND) application planned for the fourth quarter of 2025. The primary development focus is on colorectal cancer and other solid tumors.

Other names: Pan-KRas inhibitor

Targets

KRAS (Kirsten rat sarcoma viral oncogene homolog)

Beyond the preview

Go deeper on Pan-KRAS inhibitor (Leadingtac Pharmaceutical).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Pan-KRAS inhibitor (Leadingtac Pharmaceutical).

Explore the full profile